Efficacy matters: broadening complement inhibition in COVID-19 – Authors' reply

Research output: Contribution to journal › Comment/Letter to the editor › Academic

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{2e22eec2983b4e048e4e4dd5f0e04d2f,

title = "Efficacy matters: broadening complement inhibition in COVID-19 – Authors' reply",

author = "Vlaar, \{Alexander P. J.\} and \{de Bruin\}, Sanne and Brouwer, \{Matthijs C.\} and \{van de Beek\}, Diederik",

year = "2021",

month = feb,

doi = "10.1016/S2665-9913(20)30424-0",

language = "English",

volume = "3",

pages = "e95--e96",

journal = "The Lancet Rheumatology",

issn = "2665-9913",

publisher = "Elsevier Ltd",

number = "2",

}

TY - JOUR

T1 - Efficacy matters: broadening complement inhibition in COVID-19 – Authors' reply

AU - Vlaar, Alexander P. J.

AU - de Bruin, Sanne

AU - Brouwer, Matthijs C.

AU - van de Beek, Diederik

PY - 2021/2

Y1 - 2021/2

UR - https://www.scopus.com/pages/publications/85099135704

U2 - 10.1016/S2665-9913(20)30424-0

DO - 10.1016/S2665-9913(20)30424-0

M3 - Comment/Letter to the editor

C2 - 33521673

SN - 2665-9913

VL - 3

SP - e95-e96

JO - The Lancet Rheumatology

JF - The Lancet Rheumatology

IS - 2

ER -